These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38553761)

  • 1. Vaccination with a combination of STING agonist-loaded lipid nanoparticles and CpG-ODNs protects against lung metastasis via the induction of CD11b
    Khalifa AM; Nakamura T; Sato Y; Harashima H
    Exp Hematol Oncol; 2024 Mar; 13(1):36. PubMed ID: 38553761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer Immunotherapy with Lipid Nanoparticles Loaded with a Stimulator of Interferon Genes Agonist against Renal Tumor Lung Metastasis.
    Nakamura T; Sasaki S; Sato Y; Harashima H
    Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of in vivo fate of STING agonist-loaded lipid nanoparticles on antitumor immunity.
    Endo R; Ueda T; Nagaoki T; Shima N; Sato Y; Harashima H; Nakamura T
    J Control Release; 2024 Aug; 372():609-618. PubMed ID: 38942082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma.
    Nakamura T; Miyabe H; Hyodo M; Sato Y; Hayakawa Y; Harashima H
    J Control Release; 2015 Oct; 216():149-57. PubMed ID: 26282097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mn
    Ling K; Zheng J; Jiang X; Huang W; Mai Y; Liao C; Fan S; Bu J; Li R; Zeng B; Zheng Q; Huang R; Li Z; Wong NK; Jiang H
    ACS Nano; 2024 Jan; 18(4):2841-2860. PubMed ID: 38251849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of cancer vaccine with CD122-biased IL-2/anti-IL-2 Ab complex shapes the stem-like effector NK and CD8
    Shimizu K; Ueda S; Kawamura M; Aoshima H; Satoh M; Nakabayashi J; Fujii SI
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37400134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody.
    Khalifa AM; Nakamura T; Sato Y; Sato T; Hyodo M; Hayakawa Y; Harashima H
    Int J Pharm; 2022 Aug; 624():122034. PubMed ID: 35863595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
    Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
    Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons.
    Sun S; Zhang X; Tough D; Sprent J
    Springer Semin Immunopathol; 2000; 22(1-2):77-84. PubMed ID: 10944802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyethylenimine-Mediated CpG Oligodeoxynucleotide Delivery Stimulates Bifurcated Cytokine Induction.
    Cheng T; Miao J; Kai D; Zhang H
    ACS Biomater Sci Eng; 2018 Mar; 4(3):1013-1018. PubMed ID: 33418784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity
    Li T; Wu J; Zhu S; Zang G; Li S; Lv X; Yue W; Qiao Y; Cui J; Shao Y; Zhang J; Liu YJ; Chen J
    Front Pharmacol; 2020; 11():8. PubMed ID: 32116691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory effects of CpG oligodeoxynucleotides on established th2 responses.
    Kitagaki K; Jain VV; Businga TR; Hussain I; Kline JN
    Clin Diagn Lab Immunol; 2002 Nov; 9(6):1260-9. PubMed ID: 12414759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation.
    Sun Y; Hu H; Liu Z; Xu J; Gao Y; Zhan X; Zhou S; Zhong W; Wu D; Wang P; Rao Z; Kong L; Zhou H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides.
    Kawarada Y; Ganss R; Garbi N; Sacher T; Arnold B; Hämmerling GJ
    J Immunol; 2001 Nov; 167(9):5247-53. PubMed ID: 11673539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations - a review, hypothesis and implications.
    Becker Y
    Virus Genes; 2005 Mar; 30(2):251-66. PubMed ID: 15744581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
    Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
    Front Oncol; 2021; 11():621550. PubMed ID: 33777767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.